Advice

following an abbreviated submission:


indacaterol/mometasone furoate (Atectura Breezhaler®) is accepted for use within NHSScotland.

Indication under review: as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.

Indacaterol/mometasone furoate (Atectura Breezhaler®) offers an additional treatment choice of inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) in a single inhaler. SMC has previously accepted alternative LABA / ICS combinations for use in asthma.

Download detailed advice729KB (PDF)

Download

Medicine details

Medicine name:
indacaterol/mometasone furoate (Atectura Breezhaler)
SMC ID:
SMC2356
Indication:

As a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists

Pharmaceutical company
Novartis Pharmaceuticals UK Ltd
BNF chapter
Respiratory system
Submission type
Abbreviated
Status
Accepted
Date advice published
10 May 2021